• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.

作者信息

Hulin Cyrille, Beksac Meral, Goodman Hugh J, Spicka Ivan, Alegre Adrian, Prince Miles, Campana Frank, Finn Greg, Le-Guennec Solenn, Macé Sandrine, Muccio Stéphane, Tavernier Alexandra, Rouchon Marie-Claude, Richardson Paul G

机构信息

Department of Hematology, Hospital De Haut Leveque, University Hospital, Pessac, France.

Ankara University School of Medicine, Department of Hematology, Ankara, Turkey.

出版信息

Blood Cancer J. 2021 Oct 20;11(10):169. doi: 10.1038/s41408-021-00562-9.

DOI:10.1038/s41408-021-00562-9
PMID:34671024
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8528829/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9332/8528829/f20cb46d29cb/41408_2021_562_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9332/8528829/f20cb46d29cb/41408_2021_562_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9332/8528829/f20cb46d29cb/41408_2021_562_Fig1_HTML.jpg

相似文献

1
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.isatuximab联合泊马度胺及地塞米松治疗多发性骨髓瘤时的抗体干扰及反应动力学
Blood Cancer J. 2021 Oct 20;11(10):169. doi: 10.1038/s41408-021-00562-9.
2
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.依既往治疗线数和难治状态分层的复发/难治性多发性骨髓瘤患者中伊沙佐米联合泊马度胺和地塞米松治疗：ICARIA-MM 亚组分析。
Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29.
3
[Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].埃罗妥珠单抗联合泊马度胺及地塞米松治疗多发性骨髓瘤
Internist (Berl). 2019 Jun;60(6):658-660. doi: 10.1007/s00108-019-0592-9.
4
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.依沙佐米昔单抗治疗复发/难治性多发性骨髓瘤：III 期 ICARIA-MM 研究关键亚组分析综述。
Future Oncol. 2021 Dec;17(34):4797-4812. doi: 10.2217/fon-2021-0568. Epub 2021 Sep 15.
5
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.埃罗妥珠单抗联合泊马度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.
6
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.帕博利珠单抗联合泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者（KEYNOTE-183）：一项随机、开放标签的3期试验。
Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
7
Isatuximab: First Approval.依沙妥昔单抗：首次获批
Drugs. 2020 Jun;80(9):905-912. doi: 10.1007/s40265-020-01311-1.
8
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
9
Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan.依沙佐米联合泊马度胺-地塞米松治疗复发/难治性多发性骨髓瘤：日本的上市后监测。
Int J Hematol. 2024 Aug;120(2):217-228. doi: 10.1007/s12185-024-03800-5. Epub 2024 May 29.
10
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.一项关于伊沙妥昔单抗联合泊马度胺/地塞米松治疗复发/难治性多发性骨髓瘤的 1b 期研究。
Blood. 2019 Jul 11;134(2):123-133. doi: 10.1182/blood-2019-02-895193. Epub 2019 Mar 12.

引用本文的文献

1
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.isatuximab联合卡非佐米和地塞米松治疗复发/难治性多发性骨髓瘤患者的临床疗效
Eur J Haematol. 2025 Jan;114(1):105-114. doi: 10.1111/ejh.14314. Epub 2024 Oct 6.

本文引用的文献

1
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
2
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.解读多发性骨髓瘤临床试验数据：将研究结果转化至实际应用场景。
Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0.
3
Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.
治疗性单克隆抗体对多发性骨髓瘤患者常规血清蛋白电泳和免疫固定的干扰：达妥木单抗和埃罗妥珠单抗的检测频率和持续时间。
Am J Clin Pathol. 2018 Jul 3;150(2):121-129. doi: 10.1093/ajcp/aqy037.
4
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.微小残留病与多发性骨髓瘤患者更好的生存结果的关联：一项荟萃分析。
JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.
5
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.微小残留病状态在新诊断的多发性骨髓瘤患者临床结局中的作用：一项荟萃分析。
Bone Marrow Transplant. 2016 Dec;51(12):1565-1568. doi: 10.1038/bmt.2016.222. Epub 2016 Sep 5.
6
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.监测接受达雷妥尤单抗治疗的多发性骨髓瘤患者：揭示单克隆抗体干扰。
Clin Chem Lab Med. 2016 Jun 1;54(6):1095-104. doi: 10.1515/cclm-2015-1031.
7
New criteria for response assessment: role of minimal residual disease in multiple myeloma.反应评估的新标准：微小残留病在多发性骨髓瘤中的作用。
Blood. 2015 May 14;125(20):3059-68. doi: 10.1182/blood-2014-11-568907. Epub 2015 Apr 2.
8
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
9
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.新型药物治疗老年骨髓瘤患者的完全缓解与长期无进展生存和总生存相关：对 1175 例患者的分析。
Blood. 2011 Mar 17;117(11):3025-31. doi: 10.1182/blood-2010-09-307645. Epub 2011 Jan 12.
10
Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.多发性骨髓瘤中实现完全缓解的重要性，以及新型药物的影响。
J Clin Oncol. 2010 May 20;28(15):2612-24. doi: 10.1200/JCO.2009.25.4250. Epub 2010 Apr 12.